Introduction
The efficacy of inhaled corticosteroids for the treatment of asthma is well documented, with national and international treatment guidelines recommending their use as first-line therapy for all except mild asthma (1,2). These guidelines use a step-wise approach to therapy with increases in the dose of inhaled corticosteroids recommended if disease control is considered inadequate. In practice, many physicians establish the optimum maintenance dose by initiating therapy at a high dose, which is then reduced once symptoms have been controlled, a practice now endorsed by the new British Asthma Guidelines (3).
However, the use of high doses of inhaled corticosteroids in greater numbers of patients and for longer periods has led to concern over the potential for systemic adverse effects, most notably suppression of the hypothalamic pituitary adrenal (HPA) axis, effects on bone metabolism and effects on growth of children (4-6). These systemic effects are due to a combination of the swaIlowed and inhaled portion of the drug.
Fluticasone propionate (FP) is a new generation, topical glucocorticosteroid for the treatment of asthma in adults and children. In vitro data have shown FP to be more potent at a given microgram dose than either budesonide (Bud) or beclomethasone dipropionate (BDP) (7). Furthermore, FP exhibits minimal oral systemic availability compared to Bud (< 1 vs 1 l%, respectively) (8,ll) or BDP (estimated at 20%). This is most likely due to a combination of poor gastrointestinal absorption and almost complete first-pass metabolic inactivation (9-l 1). FP therefore appears to have the potential for a greater therapeutic index than Bud or BDP. Although many studies have been performed comparing FP with Bud and BDP, controversy exists as to the relative clinical efficacy and safety of the different inhaled steroids. et al. (1995) 6.3 -9.5 22.1 0.4 Langdon & Capsey (1994) 20.8 6.6 34.9 0.005 Backman et al. (1996) 8.5 -3.4 20.4 0.16 Steinmetz & Trautmann (1996) 16.5 6.1 26.4 0.001 Ringdal et al. (1996) 15 To evaluate further the efficacy and safety of FP relative to Bud and BDP in patients with asthma, we have performed a meta-analysis of all studies (as of December 1995) in adults and children where FP was used at half the microgram dose (or less) of Bud or BDP and morning peak expiratory flow rate (PEFR) was an outcome measure. In vitro and initial clinical studies have indicated a 2: 1 potency ratio of FP to and FP is recommended for use at half the dose of Bud and BDP in national and international guidelines (3).
Methods

SELECTION OF STUDIES
The meta-analysis included seven studies evaluating the safety and efficacy of FP vs and seven studies vs BDP (12,20&25). Criteria for inclusion were studies of FP vs Bud or BDP in which FP was used at half or less of the dose of Bud or BDP, in which daily morning peak expiratory flow rate (PEFR) was an outcome measure and which were reported by December 1995. One further study comparing FP vs BDP in China was known to have completed patient entry, but the data were not reported or available. The objective of the analysis was to evaluate all the data available to support or refute the hypothesis that FP at half the dose (or less) is as effective as Bud and BDP when used to treat patients with asthma. Therefore, studies comparing the drugs in healthy volunteers or at equal doses were not included EFFICACY In all trials, mean morning PEFR was recorded daily by the subjects on a diary card during both the run-in phase and the treatment phase. Measurements recorded on the 7 days immediately prior to administration of the first dose of study medication were combined and divided by the number of days for which data were available for that 7-day period to obtain a baseline measurement.
To calculate the mean morning PEFR for the treatment phase, the end of treatment was determined from the protocol, and the last week was nominally described as ending 3 days before the last day of the protocol. This ensured that missing values towards the end of the study, often due to administrative reasons, did not result in substantial missing data. Three days was chosen arbitrarily as the minimum necessary, whilst maintaining as long a period of treatment exposure as possible. Morning PEFR values recorded on this day and the previous 6 days were then pooled and divided by the number of days for which data were available. This value was then used as the mean morning PEFR at the end of therapy. It was necessary to use this method to determine mean morning PEFR as it was found that many subjects did not complete their diaries in full for their final week of treatment. Furthermore, in For each patient, the time to 10% improvement was determined as the day at which the diary card morning PEFR reached 10% or more of the mean baseline value. Exacerbations of asthma were collected from the diary cards, and the overall percentage of patients in each trial with exacerbations was calculated.
SYSTEMIC ACTIVITY
Morning serum cortisol levels (8810 am) were used as a measure of systemic activity. Serum cortisols were measured in 12 of the 14 trials included in this metaanalysis. For each of these studies, the ratio between the mean serum cortisol level (nmol l-') at baseline (a day prior to taking treatment) and at the end of therapy (last day of treatment) was determined for both study drugs and the mean difference between cortisol ratios on FP and Bud or BDP was compared.
STATISTICAL ANALYSIS
To perform the meta-analysis on the mean morning PEFR, each separate trial was analysed with all patients included and using a common model involving centre, baseline and treatment factors [SA@ Proc GLM (PC Version 6.08)].
Similarly, in the meta-analysis for the plasma cortisol, each separate trial was analysed using the logarithm of the 'end-treatment' plasma cortisol as the response variable with centre, logged baseline and treatment factors included in the model. Results are given as ratios following back transformation.
As the analysis includes all worldwide studies performed at a ratio of at least 1:2, a fixed-effect model was used for the meta-analysis.
A pooled weighted mean of all the separate estimates of the treatment differences from each individual trial was calculated using the inverse variance from each trial as weights.
The common variance estimate of the pooled treatment difference was computed from the inverse sum of the square root of the above weights. This pooled variance was then used to calculate the confidence limits of the pooled mean treatment difference (ratio). (26) . No evidence was found for any heterogeneity among the estimates of morning PEFR or cortisol.
Results
DEMOGRAPHICS
Studies included in this analysis encompassed all severities of asthma in adult and paediatric patients, except for patients on regular oral steroids. Seven studies compared doses of FP 200-8OOpg day-' with Bud 400~16OO~g day -' administered via powder and metered-dose inhaler delivery systems. A total of 1980 patients recorded efficacy data in these trials, 1000 of whom were treated with FP and 980 with Bud. Individual study details are summarized in Tables l-3 . Seven studies compared FP 200-1000 pg day -' with BDP 400-2000,~~g day-'.
A total of 1584 patients recorded efficacy data in these trials, 780 of whom were treated with FP and 804 with BDP. Individual study details are summarised in Tables 4-6 . Two studies involved children, one with Bud and one with BDP. The remaining 12 studies were carried out in adults, covering all asthma severities up to moderate severe, and employed a variety of powder and aerosol delivery devices. All studies were controlled, with eight being blinded and six open-label.
EFFICACY FP vs BUD
In all studies comparing FP at half the dose (or less) with Bud, mean improvements in morning PEFR on therapy from baseline favoured FP, attaining statistical significance in four of the seven trials (Fig. 1) . The pooled analysis across all seven studies also significantly favoured FP, with a mean difference in improvement in morning PEFR on therapy between FP and Bud of + 11 1 min-' (95% confidence interval +7 to + 15).
FP vs BDP
There were no statistically significant differences in improvement in morning PEFR between FP at half the dose compared with BDP in any of the seven trials (Fig. 2) . The pooled analysis showed a non-significant trend in favour of FP with a mean difference in improvement in morning PEFR on therapy between FP and BDP of +3 1 min-' (950/ o confidence interval -0.9 to +7).
SAFETY FP vs BUD
Mean changes in serum cortisol levels on therapy were determined in five studies comparing FP at half the dose (or less) with Bud. As would be expected, no significant intergroup differences in serum cortisols were detected at low doses. However, significant differences in favour of FP were apparent at higher dose levels (FP 2 500 pg day ~ 1 and Bud 2 1200 pg day -') ( Fig. 3) . The pooled analysis across all five studies also revealed a significant difference in co&sol ratios favouring FP (ratio = 1.09 nmol 1~ '; 95% confidence interval 1.03-1.15). 
FP vs BDP
however, the pooled analysis across all seven studies showed no significant difference in cortisol ratios Mean changes in serum cortisol levels did not differ significantly between treatments in the studies comparing FP at half the dose with BDP below 1OOOpg day-' (Fig. 4) . At higher doses, a difference in favour of FP was apparent, (ratio= 1.03 nmol l-i; 95% confidence interval 0.99-1.07).
Exacerbations of asthma were also collected for patients in these studies. These results showed that exacerbations occurred for between 4 and 10% of patients. No apparent differences were seen for the percentage of patients suffering from an exacerbation, irrespective of their treatment, suggesting a similar effect on asthma control.
Discussion
FP KS BUD
The results of this meta-analysis indicate that FP at half the dose (or less) is more effective for the treatment of asthma than Bud, irrespective of delivery system, as indicated by improvements in morning PEFR. This analysis also reinforces the findings of some individual studies (13-19) which have been used to claim a 2:l potency ratio compared with Bud. The pooled analysis in mean changes in serum cortisol levels favoured FP over Bud, although, as might be anticipated, significant differences between these two corticosteroids were only seen at higher dose levels. Limitations of the analysis focus on the fact that some of the studies were open-label, because of difficulty in obtaining placebo devices for Bud. However, it is noteworthy that the double blind, double-dummy study significantly favoured FP, both in terms of efficacy and safety, and reflected the pooled analysis result.
The results of this meta-analysis, therefore, contrast with some reports which have suggested that FP has greater systemic activity than Bud in normal volunteers (27729) highlighting the difficulties with extrapolating findings from normal subjects to patients with clinical disease. There are a number of possible explanations for these different findings. Hypothalamic-pituitary-adrenal (HPA) axis function may be less affected by doses of inhaled corticosteroid in patients with normal lifestyle functioning than those in rested normal volunteers.
The pathophysiological pulmonary changes associated with asthma may result in clinically relevant differences in the pattern of drug distribution and absorption in the lung between asthmatic patients and normal subjects, and such differences could explain alterations in the degree or rate of systemic drug absorption (30) . Finally, in patients with asthma, differences in the respiratory fraction between delivery devices may not account for the variation in efficacy and systemic activity seen in normal subjects (31) .
FP KS BDP
Comparisons between FP at half the dose and BDP showed that both treatments were equally as effective in terms of changes in PEFR. Mean changes in serum cortisol levels showed that at doses 275Opg day-' (and also at one of the lower doses), differences between FP and BDP were just statistically significant. However, no overall difference was observed between these two drugs in the pooled analysis.
Summary
While results of the individual studies generally revealed no significant differences in plasma cortisol levels between FP YS Bud, and also FP vs BDP, at low doses, differences in favour of FP at higher dose levels were detected. This may have important implications for patient management, as the major concern with currently available drugs of this class is the apparent increased risk of systemic effects, such as suppression of the HPA axis and effects on bone metabolism, at high doses (4-6).
The meta-analyses demonstrate that FP across a dose range of 200-8OOpg day -I is more effective than Bud 400-16OOpg day-' and across a dose range of 200-1000 pug day ~ ' as effective as BDP 400&2OOO~g day ~ ' for the treatment of asthma. FP is also less likely to suppress mean morning serum cortisol levels than Bud, particularly/ moderate to severe asthma where higher dosages of inhaled corticosteroids are required. Therefore, the results of this meta-analysis confirm that FP at half the clinically recommended dose of Bud or BDP is an effective treatment option for asthma of all severities in both adult and paediatric patients. Therefore, FP provides the potential for an improved therapeutic efficacy to safety ratio compared with Bud and BDP. 
